TY - JOUR T1 - Relationship between the type of hormone replacement therapy and incidence of breast cancer in Korea. AU - Baek,J K, AU - Kim,H I, AU - Kang,M J, AU - Seon,K E, AU - Kim,E H, AU - Seo,S K, Y1 - 2022/06/08/ PY - 2022/6/8/entrez PY - 2022/6/9/pubmed PY - 2022/6/9/medline KW - Breast cancer KW - hormone replacement therapy KW - incidence KW - menopause KW - postmenopausal KW - tibolone SP - 1 EP - 7 JF - Climacteric : the journal of the International Menopause Society JO - Climacteric N2 - OBJECTIVE: This study aimed to investigate the relationship between hormone replacement therapy (HRT) types and breast cancer (BC) incidence in postmenopausal women in Korea. METHODS: The nested case-control study used data from the National Health Insurance Service database. Among the women aged ≥50 years who menopaused between 2004 and 2007, BC incidence up to 2017 was analyzed in 36,446 women using or having used HRT for >1 year and in 36,446 women who did not use any HRT for more than 1 year. HRT types and duration were classified into three categories. RESULTS: BC risk (BCR) decreased with tibolone use for all ages. With HRT initiation in women aged ≥50 years, BCR was lower with tibolone and estrogen-progestogen therapy. HRT for <3 years showed lower BCR with tibolone, while higher BCR was observed with estrogen-only therapy. BCR was lower in women of all ages on HRT for >5 years than in the control group. CONCLUSIONS: For women in their 50s, tibolone use lowers BCR; for all ages, the use of any HRT for >5 years showed lower BCR in Korea. These divergent results from western countries could be associated with the specific characteristics of BC in Korea. SN - 1473-0804 UR - https://www.unboundmedicine.com/medline/citation/35674251/Relationship_between_the_type_of_hormone_replacement_therapy_and_incidence_of_breast_cancer_in_Korea. DB - PRIME DP - Unbound Medicine ER -